Retraction Note: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation

Tahereh Javaheri^{1

2}, Zahra Kazemi^{3

4}, Jan Pencik^{1

3

5}, Ha T T Pham^{1

2}, Maximilian Kauer⁶, Rahil Noorizadeh^{1

2}, Barbara Sax¹, Harini Nivarthi^{1

7}, Michaela Schlederer^{1

3

5}, Barbara Maurer^{1

2}, Maximillian Hofbauer¹, Dave N T Aryee^{6

8}, Marc Wiedner^{1

7}, Eleni M Tomazou⁶, Malcolm Logan⁹, Christine Hartmann¹⁰, Jan P Tuckermann¹¹, Lukas Kenner^{1

3

5

12}, Mario Mikula^{3

13}, Helmut Dolznig^{3

13}, Aykut Üren¹⁴, Günther H Richter¹⁵, Florian Grebien¹, Heinrich Kovar^{6

8}, Richard Moriggl^{16

17

18}

Affiliations

¹ Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria.
² Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria.
³ Medical University of Vienna, Vienna, Austria.
⁴ Center of Physiology and Pharmacology, Vienna, Austria.
⁵ Clinical Institute of Pathology, Vienna, Austria.
⁶ Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.
⁷ CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
⁸ Department of Pediatrics, Medical University of Vienna, Vienna, Austria.
⁹ Randall Division of Cell and Molecular Biophysics, King's College London, London, UK.
¹⁰ Department of Bone and Skeletal Research, Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany.
¹¹ Institute of General Zoology and Endocrinology, University of Ulm, Ulm, Germany.
¹² University of Veterinary Medicine, Vienna, Austria.
¹³ Institute of Medical Genetics, Vienna, Austria.
¹⁴ Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, USA.
¹⁵ Children's Cancer Research Centre and Department of Pediatrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
¹⁶ Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria. richard.moriggl@lbicr.lbg.ac.at.
¹⁷ Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria. richard.moriggl@lbicr.lbg.ac.at.
¹⁸ Medical University of Vienna, Vienna, Austria. richard.moriggl@lbicr.lbg.ac.at.

PMID: 31406155
PMCID: PMC6690967
DOI: 10.1038/s41419-019-1853-1

Retraction Note: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation

Tahereh Javaheri et al. Cell Death Dis. 2019.

. 2019 Aug 13;10(8):605.

doi: 10.1038/s41419-019-1853-1.

Authors

Affiliations

¹ Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria.
² Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria.
³ Medical University of Vienna, Vienna, Austria.
⁴ Center of Physiology and Pharmacology, Vienna, Austria.
⁵ Clinical Institute of Pathology, Vienna, Austria.
⁶ Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.
⁷ CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
⁸ Department of Pediatrics, Medical University of Vienna, Vienna, Austria.
⁹ Randall Division of Cell and Molecular Biophysics, King's College London, London, UK.
¹⁰ Department of Bone and Skeletal Research, Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany.
¹¹ Institute of General Zoology and Endocrinology, University of Ulm, Ulm, Germany.
¹² University of Veterinary Medicine, Vienna, Austria.
¹³ Institute of Medical Genetics, Vienna, Austria.
¹⁴ Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, USA.
¹⁵ Children's Cancer Research Centre and Department of Pediatrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
¹⁶ Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria. richard.moriggl@lbicr.lbg.ac.at.
¹⁷ Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria. richard.moriggl@lbicr.lbg.ac.at.
¹⁸ Medical University of Vienna, Vienna, Austria. richard.moriggl@lbicr.lbg.ac.at.

PMID: 31406155
PMCID: PMC6690967
DOI: 10.1038/s41419-019-1853-1

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

PubMed Disclaimer

Retraction of

Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.
Javaheri T, Kazemi Z, Pencik J, Pham HT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DN, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R. Javaheri T, et al. Cell Death Dis. 2016 Oct 13;7(10):e2419. doi: 10.1038/cddis.2016.268. Cell Death Dis. 2016. Retraction in: Cell Death Dis. 2019 Aug 13;10(8):605. doi: 10.1038/s41419-019-1853-1. PMID: 27735950 Free PMC article. Retracted.

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Retraction Note: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation

Affiliations

Retraction Note: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation

Authors

Affiliations

Abstract

Retraction of

Publication types

LinkOut - more resources

Full Text Sources